NCT01435031 - EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions | Biotech Hunter

Enrollment

250

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

February 28, 2014

Study Completion Date

December 31, 2017

Conditions

Coronary Artery Disease (CAD)Chronic Total Occlusion (CTO)

Interventions

DEVICE

CTO Treatment Device

"Subjects receiving at least 1 of the following for the treatment of CTO:~* XIENCE V® and/or XIENCE nano™ and/or XIENCE PRIME™ LL Everolimus Eluting Coronary Stent~* HT PROGRESS and/or HT PILOT guide wires in recanalization~* MINI-TREK Coronary Dilatation Catheter in predilatation"

Trial Locations (1)

95054

Abbott Vascular, Santa Clara